Skip to content
10-Q

Quarterly Report

ImmunoCellular Therapeutics, Ltd.

0000822411-18-000007

← back to feed
Filed
May 14, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2018 · May 4, 2018 41.93M sh
Operating Cash Flow Q1 2018 · Mar 31, 2018 −$1.6M
Operating Cash Flow Q1 2018 · Mar 31, 2017 −$6.07M
Cash And Equivalents Q1 2018 · Mar 31, 2018 $5.03M
Cash And Equivalents Q1 2018 · Dec 31, 2017 $6.63M
Cash And Equivalents Q1 2018 · Mar 31, 2017 $5.34M
Cash And Equivalents Q1 2018 · Dec 31, 2016 $11.44M
Stockholders Equity Q1 2018 · Mar 31, 2018 $3.67M
Stockholders Equity Q1 2018 · Dec 31, 2017 $4.65M
Current Liabilities Q1 2018 · Mar 31, 2018 $1.49M
Current Liabilities Q1 2018 · Dec 31, 2017 $2.36M
Current Assets Q1 2018 · Mar 31, 2018 $5.16M
Current Assets Q1 2018 · Dec 31, 2017 $7.01M
Total Assets Q1 2018 · Mar 31, 2018 $5.16M
Total Assets Q1 2018 · Dec 31, 2017 $7.01M
Sga Expense Q1 2018 · Mar 31, 2018 $734.58K
Sga Expense Q1 2018 · Mar 31, 2017 $793.18K
Rd Expense Q1 2018 · Mar 31, 2018 $290.62K
Rd Expense Q1 2018 · Mar 31, 2017 $4.69M
Net Income Q1 2018 · Mar 31, 2018 −$1.02M
Net Income restated Q1 2018 · Mar 31, 2017 −$5.93M
Operating Income Q1 2018 · Mar 31, 2018 −$1.03M
Operating Income Q1 2018 · Mar 31, 2017 −$5.48M
Revenue Q1 2018 · Mar 31, 2018 $0
Revenue Q1 2018 · Mar 31, 2017 $0